Chimerix, Inc. CMRX,
a biopharmaceutical company developing novel, oral antivirals in areas of high
unmet medical need, today announced that its investigational broad-spectrum
antiviral brincidofovir has been selected as one of two investigational agents
to be evaluated in a clinical study in patients with confirmed Ebola Virus
Disease in west Africa. Chimerix and the University of Oxford are in the
process of finalizing a definitive agreement for supplying brincidofovir for
the planned clinical trial.
With funding provided by the Wellcome Trust, the trial will be led by the
University of Oxford on behalf of the International Severe Acute Respiratory
and Emerging Infection Consortium (ISARIC), with operational support in west
Africa provided by Médecins Sans Frontières (MSF). The World Health
Organization (WHO) and local health authorities are also participating in this
clinical research. The west African trials will require the review and
authorization of local health ministers and ethics boards prior to
commencement.
"During what is perhaps the greatest acute public health crisis of our
lifetimes, we want to recognize the profound sense of urgency and myriad
scientific, medical, and clinical development issues being addressed together
with multiple federal and international partners. We look forward to
finalizing the trial arrangements with ISARIC as soon as possible to allow a
better understanding of the potential benefit that brincidofovir could have in
this Ebola Virus Disease outbreak," said M. Michelle Berrey, M.D., M.P.H.,
President and Chief Executive Officer of Chimerix.
In October, the U.S. Food and Drug Administration (FDA) authorized a Phase 2
(Study 205) single-arm study to evaluate the safety and antiviral activity of
brincidofovir in subjects with confirmed Ebola Virus Disease.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in